Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking

Burosumab, an FGF23 targeting monoclonal antibody, was approved by the FDA in 2018 for use in children and adults with X-linked hypophosphatemia (or XLH). While several clinical studies have demonstrated the long-term safety and efficacy of Burosumab, the molecular basis of FGF23-Burosumab interacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanhasut, Karnpob, Tharakaraman, Kannan, Ruchirawat, Mathuros, Satayavivad, Jutamaad, Fuangthong, Mayuree, Sasisekharan, Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427789/
https://www.ncbi.nlm.nih.gov/pubmed/36042241
http://dx.doi.org/10.1038/s41598-022-18580-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427789/
https://www.ncbi.nlm.nih.gov/pubmed/36042241
http://dx.doi.org/10.1038/s41598-022-18580-3

Ejemplares similares